US Drug Recall Register
Class II · Moderate risk Terminated Initiated Feb 2, 2017 (10 years ago)

Transderm Scop

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Labeling: Incorrect Instructions:outer carton contains the incorrect instructions for Step 2 stating "Do cut the patch" rather than the correct instructions of "Do not cut the patch". The pouch containing the patch is labeled correctly.

What was recalled

Transderm Scop (scopolamine) Transdermal System, 1.5 mg, 1 patch per pouch (NDC 66758-208-58), packaged in 4-count patches per carton (NDC 66758-208-54), Rx Only, Manufactured by ALZA Corporation, Vacaville, CA 95688 for Sandoz Inc., Princeton, NJ 08540.

Recalling firm
Sandoz Inc
NDC code
66758-208-58
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0481-2017

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Scopolamine recalls

See all
Class II · Moderate risk Terminated

Scopolamine Hydrobromide 0.25% Oph Solution

Reason Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Pharmacy Innovations D-0235-2023
Class II · Moderate risk Terminated

Transderm Scop

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 10019-553-03 D-1083-2022
Class II · Moderate risk Terminated

Transderm Scop

Reason Defective Delivery System; reports of damaged product that may alter the predicted release of scopolamine following transdermal application.

Sandoz Inc D-0133-2017
Class III · Low risk Terminated

Donnatal

Reason Labeling: Not elsewhere classified - Product label incorrectly lists Scopolamine Hydrocodone as an active ingredient on the side panel instead of Scopolamine Hydrobromide.

Rx PAK NDC 59212-425-10 D-0053-2016